Authors' recommendations: Colorectal cancer is the fourth most common cancer in the UK and starts in either the large bowel (colon) or back passage (rectum). Metastatic colorectal cancer is cancer that has spread to another part of the body, this is most commonly to the liver. Over half of patients with colorectal cancer will eventually develop metastatic disease after their first treatment for colorectal cancer. Ninedanib is a new drug for the treatment of colorectal cancer given as a tablet twice a day. Some studies have suggested nintedanib may be helpful for patients whose first treatment has failed and whose disease has spread and become metastatic. If nintedanib is licensed for use in the UK, it could be a new treatment option for patients with metastatic colorectal cancer. This may improve survival and the quality of life of patients when current treatments have stopped working.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/nintedanib-vargatef-for-metastatic-colorectal-cancer-second-and-subsequent-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)